Angitia Biopharmaceuticals Presents First-in-Human Data on AGA2118 for Osteoporosis at ASBMR 2024

Clinical data demonstrated treatment with AGA2118 resulted in dose-dependent increases in bone mineral density. News provided by.
1 day ago
from: FOX40

American Society for Bone and Mineral Research, Medicine, Osteoporosis, Sclerostin